Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC)
N Dickgreber, JCH Yang, MJ Ahn, B Halmos, V Hirsh, M Hochmair, B Levy, F de Marinis, T Mok, K O'Byrne, I Okamoto, M Schuler, M Sebastian, R Shah, EH Tan, N Yamamoto, A Märten, D Massey, S Wind, D Carbone · Pneumologie · 2016 · Heft 02
Bibliografische Angaben
Zusammenfassung
Background: Afatinib 40 mg/day (oral) is approved for the treatment of pts with advanced EGFRm+ NSCLC. Dose adjustment is recommended according to pre-defined tolerability criteria. We performed post-hoc analyses on the influence of afatinib dose reduction on adverse events (AEs), pharmacokinetics (PK) and progression-free survival (PFS) in the Phase III LUX-Lung 3 (LL3) trial. Methods: All pts treated with afatinib in LL3 were included in the analyses (n = 229). Pts were initiated at the protocol-defined and approved dose of 40 mg. For pts experiencing drug-related grade 3 or selected prolonged grade 2 AEs, afa…
